EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Carrier-Free Cisplatin–Dactolisib Nanoparticles for Enhanced Synergistic Antitumor Efficacy

Mei Zhang, Qiuxia Tan, Sevil Gonca, Minhuan Lan iD, Bin-Zhi Qian, Xianfeng Chen iD, Norbert Radacsi iD

ACS Biomaterials Science & Engineering · 2025

DOI: 10.1021/acsbiomaterials.4c00672 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2025. Verfasst von Mei Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Engineering, Institute for Materials and Processes, University of Edinburgh, Robert Stevenson Road, Edinburgh EH9 3FB, U.K. Hauptthemen laut MEDLINE: Cisplatin, Nanoparticles, Antineoplastic Agents, Imidazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, China Scholarship Council, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin (CDDP) is one of the most commonly used chemotherapeutic agents for solid tumors and hematologic malignancy. However, its therapeutic outcomes have remained unsatisfactory due to severe side effects, a short elimination half-life, the emergence of drug resistance, and the induction of metastasis. Combination with other chemotherapeutic agents has been proposed as one strategy to address the drawbacks of CDDP-based therapy. Therefore, this study aimed to boost the antitumor efficacy of cisplatin (CDDP) with a PI3K/mTOR dual inhibitor, dactolisib (BEZ), via a carrier-free codelivery system based on the self-assembly of the coordinated CDDP-BEZ. The synthesized CDDP-BEZ nanoparticles (NPs) possess sensitive pH-responsiveness, facilitating the delivery of both drugs to cancer cells. CDDP-BEZ NPs specifically enhanced cytotoxicity in cancer cells due to the synergy between cisplatin and dactolisib, resulting in augmented DNA damage, activation of mitochondria-dependent apoptosis, and increased inhibition on the PI3K/mTOR signaling axis. The inhibition of tumor migration and metastasis by CDDP-BEZ NPs was observed both in vitro and in vivo. Our data suggest that CDDP-BEZ NPs could serve as a safe and effective platform to maximize the synergy between both drugs in combating cancer, presenting a strategy to promote the therapeutic efficacy of platinum-based chemotherapeutic agents by combining them with PI3K inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinNanoparticlesAntineoplastic AgentsImidazolesQuinolinesHumansAnimalsCell Line, TumorMiceDrug SynergismApoptosisTOR Serine-Threonine KinasesMice, NudeMice, Inbred BALB CDrug CarriersNeoplasms

Stichwörter der Autor:innen

antitumor agentscombination therapydrug deliverypure drug nanoparticlesself-assembly

Substanzen

CisplatinAntineoplastic AgentsdactolisibImidazolesQuinolinesTOR Serine-Threonine KinasesDrug Carriers

Autor:innen und Institutionen

  • School of Engineering, Institute for Materials and Processes, University of Edinburgh, Robert Stevenson Road, Edinburgh EH9 3FB, U.K.
  • School of Engineering, Institute for Bioengineering, University of Edinburgh, The King's Buildings, Edinburgh EH9 3JL, U.K.
  • Key Laboratory of Hunan Province for Water Environment and Agriculture Product Safety, College of Chemistry and Chemical Engineering, Central South University, Changsha 410083, China.
  • Medical Research Council Centre for Reproductive Health, College of Medicine and Veterinary Medicine, Queen's Medical Research Institute University of Edinburgh, Little France Crescent, Edinburgh EH16 4TJ, U.K.
  • Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, The Human Phenome Institute, Zhangjiang-Fudan International Innovation Center, Fudan University, Shanghai 200433, China.

ORCID-Profile: Minhuan Lan, Xianfeng Chen, Norbert Radacsi

Förderung

  • European Research Council
  • China Scholarship Council
  • Cancer Research UK

Zitieren

APA

Zhang, M., Tan, Q., Gonca, S., Lan, M., Qian, B. Z., Chen, X., & Radacsi, N. (2025). Carrier-Free Cisplatin–Dactolisib Nanoparticles for Enhanced Synergistic Antitumor Efficacy. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.4c00672

Vancouver

Zhang M, Tan Q, Gonca S, Lan M, Qian BZ, Chen X, et al. Carrier-Free Cisplatin–Dactolisib Nanoparticles for Enhanced Synergistic Antitumor Efficacy. ACS Biomaterials Science & Engineering. 2025. doi:10.1021/acsbiomaterials.4c00672

BibTeX
@article{Zhang2025,
  author = {Zhang, Mei and Tan, Qiuxia and Gonca, Sevil and Lan, Minhuan and Qian, Bin-Zhi and Chen, Xianfeng and Radacsi, Norbert},
  title = {Carrier-Free Cisplatin–Dactolisib Nanoparticles for Enhanced Synergistic Antitumor Efficacy},
  journal = {ACS Biomaterials Science & Engineering},
  year = {2025},
  doi = {10.1021/acsbiomaterials.4c00672}
}
Kostenlos starten →